BioSpace News Archive

Strategy Behind Lowered Insulin Prices: Novo Nordisk and Eli Lilly

After Eli Lilly announced it would take measures to cap insulin prices, Novo Nordisk will reportedly follow suit. There may be strategic reasoning behind these moves.

March 15, 2023
·
2 min read
·
Jia Jie Chen
Drug Development

Bellicum Weighs Options After Serious Safety Concerns Halt Only Trials

Bellicum Pharmaceuticals has ended the only clinical trials evaluating its GoCAR-T cell product in combination with rimiducid following serious safety concerns.

March 15, 2023
·
1 min read
·
Hayleigh Evans
Deals

Concentra’s Buy Offer May Jeopardize Jounce’s Merger with Redx

Jounce Therapeutics has received an unsolicited and non-binding acquisition proposal from Concentra Biosciences, looking to buy 100% of Jounce’s equity at a per-share price of $1.80 in cash.

March 15, 2023
·
2 min read
·
Tristan Manalac
How Executive Pay Packages are Negotiated

Some high-profile tech CEOs have recently elected to take large pay cuts to conserve cash flow. This has sparked a larger conversation about how executive compensation is decided.

March 15, 2023
·
4 min read
·
Rosemary Scott
Drug Development

Veru Moves Forward with Late-Stage COVID Study Despite FDA Roadblock

Weeks after the FDA rejected Veru’s Emergency Use Authorization bid for sabizabulin in COVID-19, the company announced plans to continue with late-stage development of the drug.

March 15, 2023
·
2 min read
·
Tristan Manalac
Business

Novartis and Pfizer-Backed Mediar Nets $85M for Fibrosis Paradigm Shift

Mediar Therapeutics added another $85 million to its coffers Wednesday to take its first-in-class fibrosis therapies to clinic.

March 15, 2023
·
2 min read
·
Kate Goodwin
Business

BrainsWay Reports Fourth Quarter and Full-Year 2022 Financial Results and Operational Highlights

BrainsWay Ltd. today reported fourth quarter and full-year 2022 financial results and provided an operational update.

March 15, 2023
·
11 min read
Zevra Therapeutics Files Definitive Proxy Statement and Mails Letter to Shareholders

Zevra Therapeutics today announced it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the Company’s 2023 Annual Meeting of Stockholders (“Annual Meeting”).

March 15, 2023
·
8 min read
Biotech Bay

Vivace Therapeutics to Unveil First Clinical Data for a Cancer Drug Targeting the Hippo Pathway

Vivace Therapeutics, Inc. today announced that the first clinical data for a cancer treatment targeting the Hippo pathway will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022.

March 15, 2023
·
2 min read
Business

LGM Pharma Reports Strong Revenues in First Year of CDMO Operations Along With Continued Growth in Its API Sourcing Business

LGM Pharma today reported strong growth in 2022 in both its long-established Active Pharmaceutical Ingredient (API) division and its new contract development and manufacturing (CDMO) division.

March 15, 2023
·
5 min read